Stay updated on Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe ClinicalTrials.gov record for a pembrolizumab study in recurrent or metastatic medullary thyroid cancer is displayed, with study details and results information. Previously, the page showed a 403 Forbidden error.SummaryDifference63%

- Check22 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide NIH notice announces an update about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1. The page still displays a 403 error rather than the study record.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.